Hydrochlorothiazide
- Generic Name
- Hydrochlorothiazide
- Brand Names
- Accuretic, Actelsar Hct, Aldactazide, Altace HCT, Atacand, Atacand Hct, Avalide, Benicar Hct, Diovan Hct, Exforge Hct, Hyzaar, Ifirmacombi, Karvezide, Lopressor Hct, Lotensin Hct, Maxzide, Micardis-hct, Olmetec Plus, Tekturna Hct, Teveten HCT, Tribenzor, Urozide, Vaseretic, Viskazide, Zestoretic, Ziac
- Drug Type
- Small Molecule
- Chemical Formula
- C7H8ClN3O4S2
- CAS Number
- 58-93-5
- Unique Ingredient Identifier
- 0J48LPH2TH
- Background
Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension. Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors or angiotensin II rec...
- Indication
Hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy. Hydrochlorothiazide is also indicated alone or in combination for the management of hypertension.
- Associated Conditions
- Calcium Nephrolithiasis, Cirrhosis of the Liver, Congestive Heart Failure (CHF), Diabetes Insipidus, Edema, Hypertension, Hypertension, Essential Hypertension, Hypokalemia caused by diuretics, Nephrotic Syndrome, Pre-Eclampsia, Premenstrual tension with edema, Renal tubular acidosis, Sodium retention, Stroke
- Associated Therapies
- -
Effect of Aliskiren and Hydrochlorothiazide on Kidney Oxygenation in Patients With Hypertension
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- Centre Hospitalier Universitaire Vaudois
- Target Recruit Count
- 24
- Registration Number
- NCT01519635
- Locations
- 🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland
Aliskiren vs Hydrochlorothiazide in Hypertensive Type II Diabetic Patients on Resistance Arteries
- Conditions
- Interventions
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2015-05-19
- Lead Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
- Registration Number
- NCT01480791
- Locations
- 🇨🇦
Cardiovascular Prevention Centre, Jewish General Hospital, Montreal, Quebec, Canada
Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age
- Conditions
- Interventions
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT01365481
- Locations
- 🇸🇬
Novartis Investigative Site, Singapore, Singapore
Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2011-01-13
- Last Posted Date
- 2014-09-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 23
- Registration Number
- NCT01276288
- Locations
- 🇩🇪
1245.42.1 Boehringer Ingelheim Investigational Site, Neuss, Germany
Hypertensive Ambulatory Trial to Compare the Efficacy of HCTZ and Lisinopril
- Conditions
- Interventions
- First Posted Date
- 2010-12-13
- Last Posted Date
- 2015-05-20
- Lead Sponsor
- Scripps Translational Science Institute
- Target Recruit Count
- 2
- Registration Number
- NCT01258764
- Locations
- 🇺🇸
Scripps Clinic, La Jolla, California, United States
Telmisartan, Amlodipine and Flow Mediated Dilation
- Conditions
- Interventions
- First Posted Date
- 2010-08-12
- Last Posted Date
- 2011-07-12
- Lead Sponsor
- Johannes Gutenberg University Mainz
- Target Recruit Count
- 576
- Registration Number
- NCT01180205
- Locations
- 🇩🇪
Universitätsmedizin Mainz, Mainz, Rheinland-Pfalz, Germany
Indapamide Versus Hydrochlorothiazide in Elderly Hypertensive Patients With Renal Insufficiency
- Conditions
- Interventions
- First Posted Date
- 2010-07-29
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 240
- Registration Number
- NCT01172431
- Locations
- 🇨🇳
Department of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
Treatment of Adiposity Related hypErTension (TARGET)
- First Posted Date
- 2010-06-07
- Last Posted Date
- 2012-02-24
- Lead Sponsor
- UMC Utrecht
- Target Recruit Count
- 32
- Registration Number
- NCT01138423
- Locations
- 🇳🇱
UMC Utrecht, Utrecht, Netherlands
Study to Determine the Effects of Nebivolol and Hydrochlorothiazide in African Americans With Hypertension
- First Posted Date
- 2009-10-22
- Last Posted Date
- 2011-05-05
- Lead Sponsor
- InVasc Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00999752
- Locations
- 🇺🇸
Atlanta Vascular Research Foundation, Tucker, Georgia, United States
Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics
- Conditions
- Interventions
- First Posted Date
- 2009-10-14
- Last Posted Date
- 2017-10-02
- Lead Sponsor
- William Beaumont Hospitals
- Registration Number
- NCT00994253
- Locations
- 🇺🇸
William Beaumont Hospital, Royal Oak, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.